Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
PT-141 vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
PT-141 is distinguished by a central melanocortin agonist with a narrow FDA-approved HSDD indication—not a general libido, sexual-performance, weight-loss, or recovery peptide; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
PT-141 is distinguished in the current record by a central melanocortin agonist with a narrow FDA-approved HSDD indication—not a general libido, sexual-performance, weight-loss, or recovery peptide. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidencePT-141
PT-141: Strong but narrow evidence. Cagrilintide: Developing human evidence.
Regulatory historyPT-141
PT-141: FDA approved for a narrow indication. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthPT-141
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
PT-141
- Hypoactive sexual desire disorder
- Sexual-brain processing
- Male erectile dysfunction — older evidence
- Obesity — sponsor topline
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
PT-141Narrow FDA indication
FDA approved as VYLEESI for acquired, generalized HSDD in certain premenopausal women. The label excludes postmenopausal women, men, and sexual-performance enhancement.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
PT-141Phase 2/3 + label
Randomized Phase 2 and Phase 3 HSDD studies, a 52-week uncontrolled extension, a small Phase 4 mechanistic study, and preliminary investigational programs. A major older male ED paper carries an Expression of Concern.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
PT-141Sponsor topline only
A short Phase 2 combination study reported an obesity signal in sponsor topline data. No full peer-reviewed report or approved weight-management indication was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
PT-141Uncontrolled kidney signal
An uncontrolled 16-person diabetic-kidney-disease program reported sponsor topline signals, with only eight six-month completers. It does not establish glucose or kidney benefit.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
PT-141No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome program was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
PT-141Label warning + contraindication
Each labeled dose can transiently increase blood pressure and reduce heart rate. VYLEESI is contraindicated in uncontrolled hypertension or known cardiovascular disease.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
PT-141VYLEESI label only
The FDA label provides product-specific instructions for a ready-to-use 1.75 mg/0.3 mL autoinjector. It does not establish reconstitution, dosing, stability, or equivalence for powders, nasal products, or unverified PT-141 materials.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Generalizability outside the labeled population and whether preliminary obesity or kidney signals survive peer review and larger controlled trials.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
PT-141
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.